ArticleScientific reports2025
The protecting role of Ganoderma lucidum polysaccharides on the retinal neurovascular units in rats with retinal ischemia-reperfusion injury.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mechanism of Ganoderma lucidum polysaccharides in the mangement of diabetes and its complications.Frontiers in pharmacology · 2026Pooled it
- Nrf2/HO-1 signaling in retinal neurodegenerative diseases: redox homeostasis, cytoprotection, and therapeutic perspectives.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study investigates the protective mechanisms of Ganoderma lucidum polysaccharides (GLP) on retinal neurovascular units (NVUs) in a rat model of retinal ischemia-reperfusion injury (RIR), focusing on oxidative stress, glial activation, vascular dysfunction, and functional recovery. RIR was induced in postnatal day 6 (P6) Sprague-Dawley rats by anterior chamber perfusion (70 mmHg intraocular pressure for 1 h). Rats were treated with daily intragastric GLP (35, 70, or 140 mg/kg/d) for 7 days (P13). Retinal integrity was assessed via: Histopathology (H&E, TUNEL staining); Electroretinography (ERG) and photopic negative response (PhNR); immunofluorescence (GFAP, IBA-1); Optical coherence tomography angiography (OCTA); Western blotting and qPCR (Nrf2/HO-1, VEGF/HIF-1α/Notch, Cx43/AQP4 pathways); Oxidative stress markers (SOD activity, MDA content by ELISA). Ganoderma lucidum polysaccharides (GLP) at 70 mg/kg significantly attenuated retinal thinning and structural disorganization induced by RIR, with reduced apoptosis observed via TUNEL staining. GLP (140 mg/kg) upregulated Nrf2 and HO-1 protein expression, increased superoxide dismutase (SOD) activity, and decreased malondialdehyde (MDA) content in retinal tissues. GLP enhanced amplitudes of ERG a-waves, b-waves, and PhNR across multiple stimulus intensities. Immunofluorescence revealed decreased GFAP and IBA-1 expression in GLP-treated groups, indicating inhibition of reactive astrogliosis and microglial activation. OCTA demonstrated reduced vascular tortuosity and increased capillary perfusion density. Down regulation of VEGF, HIF-1α, and Notch proteins, alongside upregulation of VE-cadherin and eNOS mRNA, was confirmed by Western blot and qPCR.Neurovascular unit regulation: GLP modulated Cx43 and AQP4 expression, restoring intercellular communication within retinal neurovascular units. GLP significantly counteract retinal oxidative stress injury, inhibit reactive gliosis, suppress neovascularization, stabilize endothelial adhesive junctions, and protect retinal electrophysiological function while improving vascular function in RIR rats, suggesting that GLP possess certain intervention effects on abnormalities in the retinal neurovascular unit following RIR injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.